[go: up one dir, main page]

MX2015016329A - Bloqueador de anticuerpo para la inactivacion de farmaco de proteina. - Google Patents

Bloqueador de anticuerpo para la inactivacion de farmaco de proteina.

Info

Publication number
MX2015016329A
MX2015016329A MX2015016329A MX2015016329A MX2015016329A MX 2015016329 A MX2015016329 A MX 2015016329A MX 2015016329 A MX2015016329 A MX 2015016329A MX 2015016329 A MX2015016329 A MX 2015016329A MX 2015016329 A MX2015016329 A MX 2015016329A
Authority
MX
Mexico
Prior art keywords
antibody
hinge
locker
inactivation
cleavable
Prior art date
Application number
MX2015016329A
Other languages
English (en)
Inventor
Tian-Lu Cheng
Chih-Hung Chuang
Hsiu-Fen Ko
Yun-Chi Lu
Original Assignee
Dcb Usa Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dcb Usa Llc filed Critical Dcb Usa Llc
Publication of MX2015016329A publication Critical patent/MX2015016329A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe en la presente un anticuerpo bisagra capaz de ser activado de forma selectiva en un tejido o célula diana para tratar una condición en la misma. El anticuerpo bisagra incluye un anticuerpo funcional, dos dominios inhibitorios y cuatro ligadores escindibles. El anticuerpo funcional es capaz de tratar la condición en un estado activado, y tiene dos cadenas ligeras y dos cadenas pesadas. Cada dominio inhibitorio incluye un dominio bisagra de una inmunoglobulina y consiste de dos brazos peptídicos. Cada ligador escindible incluye un substrato peptídico escindible por una enzima expresada altamente o de forma específica en el tejido o célula diana, y conecta uno de los brazos de los dominios inhibitorios a la N-terminal de una de las cadenas ligeras y cadenas pesadas del anticuerpo funcional. También se describen en la presente métodos para preparar y usar este anticuerpo bisagra.
MX2015016329A 2013-05-28 2014-05-28 Bloqueador de anticuerpo para la inactivacion de farmaco de proteina. MX2015016329A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361827763P 2013-05-28 2013-05-28
PCT/US2014/039821 WO2014193973A2 (en) 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug

Publications (1)

Publication Number Publication Date
MX2015016329A true MX2015016329A (es) 2016-07-20

Family

ID=51989521

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016329A MX2015016329A (es) 2013-05-28 2014-05-28 Bloqueador de anticuerpo para la inactivacion de farmaco de proteina.

Country Status (14)

Country Link
US (1) US10633453B2 (es)
EP (1) EP3003370B1 (es)
JP (1) JP6545666B2 (es)
KR (1) KR102182485B1 (es)
CN (1) CN105377297B (es)
AU (1) AU2014274215B2 (es)
CA (1) CA2913051C (es)
EA (1) EA035322B1 (es)
IL (1) IL242772B (es)
MX (1) MX2015016329A (es)
SG (2) SG10201710727UA (es)
TW (1) TWI582111B (es)
WO (1) WO2014193973A2 (es)
ZA (1) ZA201508673B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6545666B2 (ja) 2013-05-28 2019-07-17 ディーシービー−ユーエスエー エルエルシーＤｃｂ−Ｕｓａ Ｌｌｃ タンパク質薬物の不活性化のための抗体ロッカー
RU2715232C2 (ru) 2013-09-25 2020-02-26 Сайтомкс Терапьютикс, Инк. Субстраты матриксной металлопротеиназы и другие расщипляемые фрагменты и способы их использования
EP3192812B1 (en) 2013-12-17 2020-05-27 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN114106099B (zh) 2014-01-31 2024-05-24 西托姆克斯治疗公司 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
BR112017004802A2 (pt) 2014-09-12 2017-12-12 Genentech Inc anticorpos anti-cll-1 e imunoconjugados
MA41374A (fr) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
JP2018510143A (ja) 2015-02-25 2018-04-12 メモリアル スローン ケタリング キャンサー センター 不活化非複製改変ワクシニアウイルスアンカラ（ｍｖａ）の固形腫瘍のための単独療法又は免疫チェックポイント遮断剤併用における使用
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
HK1252158A1 (zh) * 2015-05-01 2019-05-17 Genentech, Inc. 掩蔽抗cd3抗体和使用方法
BR112017024899A2 (pt) 2015-05-21 2018-11-13 Harpoon Therapeutics, Inc. proteínas de ligação trispecíficas e métodos de uso.
EP3310378B1 (en) 2015-06-16 2024-01-24 F. Hoffmann-La Roche AG Anti-cll-1 antibodies and methods of use
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
WO2017117218A1 (en) 2015-12-30 2017-07-06 Momenta Pharmaceuticals, Inc. Methods related to biologics
BR112018016949A2 (pt) 2016-02-25 2019-01-08 Memorial Sloan Kettering Cancer Center vírus vaccinia atenuado competente em relação à replicação como deleção de timidina quinase com ou sem a expressão de flt3l ou gm-csf humano para imunoterapia de câncer
BR112018016948A2 (pt) 2016-02-25 2019-01-08 Memorial Sloan Kettering Cancer Center mva recombinante ou mva¿e3l que expressa flt3l humano e uso do mesmo como agente imunoterapêutico contra tumores sólidos
WO2017165306A1 (en) * 2016-03-20 2017-09-28 Middle Tennessee State University ASSAY FOR HIGH-THROUGHPUT lDENTIFICATION OF THERAPEUTIC COMPOUNDS
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
KR102652994B1 (ko) * 2016-05-18 2024-04-01 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
CN107446016A (zh) * 2016-05-30 2017-12-08 上海交通大学 一种硬脂酸修饰的细胞穿膜肽及其制备与应用
CN109312367B (zh) 2016-06-06 2023-04-11 艾斯克立必恩股份有限公司 用于药物递送的抗体融合蛋白
US11117968B2 (en) * 2016-11-03 2021-09-14 Bristol-Myers Squibb Company Activatable anti-CTLA-4 antibodies and uses thereof
CA3042435A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
AU2017371225A1 (en) * 2016-12-09 2019-05-16 Seagen Inc. Bivalent antibodies masked by coiled coils
AU2017388894A1 (en) * 2016-12-29 2019-08-08 Development Center For Biotechnology KLK6-mediated CNS-specific antibody prodrug activation
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
EP3625253A4 (en) 2017-05-16 2021-03-24 Scalmibio, Inc. ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE
KR102425983B1 (ko) 2017-10-13 2022-07-29 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
AU2018375375A1 (en) 2017-12-01 2020-05-28 Seagen Inc. CD47 antibodies and uses thereof for treating cancer
CR20200391A (es) 2018-02-08 2020-10-19 Genentech Inc Moléculas biespecíficas de unión al antígeno y métodos de uso
KR102245552B1 (ko) * 2018-02-28 2021-04-29 부산대학교 산학협력단 나노약물 복합체, 이의 제조방법 및 이의 용도
SG11202008589TA (en) * 2018-03-13 2020-10-29 Memorial Sloan Kettering Cancer Center Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy
WO2020056424A1 (en) 2018-09-15 2020-03-19 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
MY205459A (en) 2018-12-06 2024-10-22 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
US20220081479A1 (en) 2018-12-31 2022-03-17 Momenta Pharmaceuticals, Inc. Methods of producing ustekinumab
AR119097A1 (es) 2019-06-05 2021-11-24 Seattle Genetics Inc Métodos de purificación de anticuerpos enmascarados
US20220233709A1 (en) 2019-06-05 2022-07-28 Seagen Inc. Masked Antibody Formulations
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
CA3196539A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
US12516118B2 (en) 2020-11-04 2026-01-06 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies and anti-CD79b antibody drug conjugates
BR112023023775A2 (pt) 2021-05-14 2024-02-20 Genentech Inc Métodos para tratar um indivíduo com um distúrbio proliferativo de células positivas para cd20 e para tratar uma população de indivíduos com um distúrbio proliferativo de células positivas para cd20
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
US20240352080A1 (en) 2021-07-14 2024-10-24 Seagen Inc. Antibody Masking Domains
WO2023049825A1 (en) 2021-09-24 2023-03-30 Seagen Inc. Improved antibody masking domains
WO2023064945A2 (en) * 2021-10-15 2023-04-20 Harpoon Therapeutics, Inc. Conditional activation of immunoglobulin molecules
EP4526343A1 (en) 2022-05-16 2025-03-26 Byondis B.V. Novel masked antibodies

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
GB9322156D0 (en) 1993-10-27 1993-12-15 Univ Newcastel Upon Tyne Activation of molecules
DE69636015T2 (de) 1995-05-03 2007-01-04 Bioenhancementsments Ltd. Bispezifische antikörper in denen die bindungsfähigkeit durch eine mittels licht spaltbare gruppe reversibel inhibiert wird
US20040014652A1 (en) 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
US7238505B2 (en) 2000-10-04 2007-07-03 Ahram Biosystems Inc. Immobilized DNA polymerase
AU2002351957B2 (en) * 2001-11-12 2009-09-03 Merck Patent Gmbh Modified anti-TNF alpha antibody
EP1572908A4 (en) 2002-02-14 2008-10-22 William J Rutter CHIMERIC MOLECULES FOR ADMINISTERING CLEAVAGE TO A TREATED HOST
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
BRPI0411103B1 (pt) 2003-06-09 2019-01-15 A Mcintyre John método, e, método de obtenção e isolamento de um autoanticorpo de um fluido biológico contendo anticorpo ou de um extrato de fluido biológico contendo anticorpo
GB0404187D0 (en) 2004-02-25 2004-03-31 Biotransformations Ltd Binding agents
RU2007117716A (ru) * 2004-10-12 2008-11-20 Ампротеин Корпорейшн (Us) Химерный белок
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0605702D0 (en) 2006-03-21 2006-05-03 Biotransformations Ltd Materials and methods for immune cell stimulation
AT503902B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
GB0716160D0 (en) 2007-08-17 2007-09-26 Biotransformations Ltd Materials and methods for treating cancers which express folate receptors
CA3128656A1 (en) * 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
JP5448397B2 (ja) * 2007-09-07 2014-03-19 キヤノン株式会社 基質プローブ、多重核磁気共鳴法による酵素活性の検出方法および酵素活性のイメージング方法
WO2010077643A1 (en) 2008-12-08 2010-07-08 Tegopharm Corporation Masking ligands for reversible inhibition of multivalent compounds
CN106995495A (zh) * 2009-01-12 2017-08-01 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
CN102481341B (zh) * 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
TW201742925A (zh) * 2010-04-23 2017-12-16 建南德克公司 異多聚體蛋白質之製造
EP2609111B1 (en) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Bispecific antibodies comprising a disulfide stabilized-fv fragment
KR101612999B1 (ko) 2010-08-24 2016-04-15 로슈 글리카트 아게 활성화가능 이중특이적 항체
CA2814040C (en) 2010-10-08 2021-03-23 Joshua Michael Donaldson A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
PL2723773T3 (pl) * 2011-06-22 2018-07-31 F.Hoffmann-La Roche Ag Eliminacja komórek docelowych przez obecne w krążeniu, swoiste dla wirusa, cytotoksyczne limfocyty T z wykorzystaniem kompleksów zawierających MHC klasy I
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
MX2014011781A (es) 2012-03-30 2014-11-26 Bayer Healthcare Llc Anticuerpos regulados por proteasa.
CN104540518A (zh) 2012-04-27 2015-04-22 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
JP2015521625A (ja) 2012-06-22 2015-07-30 シトムクス セラピューティクス，インコーポレイティド 抗−Ｊａｇｇｅｄ１／Ｊａｇｇｅｄ２交差反応性抗体、活性化可能抗−Ｊａｇｇｅｄ抗体及びそれらの使用方法
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
WO2014052462A2 (en) 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
CN105209496A (zh) * 2013-03-15 2015-12-30 拜尔健康护理有限责任公司 针对组织因子途径抑制剂的前体药物抗体
JP6545666B2 (ja) 2013-05-28 2019-07-17 ディーシービー−ユーエスエー エルエルシーＤｃｂ−Ｕｓａ Ｌｌｃ タンパク質薬物の不活性化のための抗体ロッカー
KR102216088B1 (ko) 2013-07-25 2021-02-15 싸이톰스 테라퓨틱스, 인크. 다중특이성 항체, 다중특이성 활성화 가능한 항체 및 그의 사용 방법
RU2715232C2 (ru) 2013-09-25 2020-02-26 Сайтомкс Терапьютикс, Инк. Субстраты матриксной металлопротеиназы и другие расщипляемые фрагменты и способы их использования
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
DE102014201538A1 (de) 2014-01-29 2015-07-30 Robert Bosch Gmbh Verfahren zum Ansteuern eines Parkplatz-Managementsystems für mindestens einen Parkplatz und Parkplatz-Managementsystem für mindestens einen Parkplatz

Also Published As

Publication number Publication date
EP3003370A2 (en) 2016-04-13
ZA201508673B (en) 2017-05-31
JP2016520614A (ja) 2016-07-14
HK1221426A1 (en) 2017-06-02
EP3003370B1 (en) 2020-01-22
JP6545666B2 (ja) 2019-07-17
TW201520230A (zh) 2015-06-01
CN105377297A (zh) 2016-03-02
US10633453B2 (en) 2020-04-28
AU2014274215A1 (en) 2015-12-03
EP3003370A4 (en) 2017-01-25
EA201592049A1 (ru) 2016-04-29
CA2913051A1 (en) 2014-12-04
AU2014274215B2 (en) 2019-02-28
IL242772B (en) 2020-04-30
WO2014193973A2 (en) 2014-12-04
KR20160032041A (ko) 2016-03-23
KR102182485B1 (ko) 2020-11-25
EA035322B1 (ru) 2020-05-28
TWI582111B (zh) 2017-05-11
CA2913051C (en) 2023-09-05
WO2014193973A3 (en) 2015-02-19
SG11201509595PA (en) 2015-12-30
SG10201710727UA (en) 2018-02-27
US20160185875A1 (en) 2016-06-30
CN105377297B (zh) 2019-09-17

Similar Documents

Publication Publication Date Title
MX2015016329A (es) Bloqueador de anticuerpo para la inactivacion de farmaco de proteina.
GEAP202114720A (en) Constructs having a sirp-alpha domain or variant thereof
EP4434587A3 (en) Antibody variable domain combinations targeting the nkg2d receptor
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
MX2022008184A (es) Anticuerpos anti pd-1 y anti-lag3 para usarse en el tratamiento de cancer.
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
BR112015013127A2 (pt) imunoterapia com agentes de ligação
CY1119743T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
BR112016011025A2 (pt) polipeptídeos anticorpo e seus usos
TN2013000390A1 (en) Bispecific binding molecules binding to vegf and ang2
NZ612394A (en) Tnf-α binding proteins
PH12014502179B1 (en) Ang2-binding molecules
UA113712C2 (xx) Антитіло до fap і способи його застосування
WO2013072813A3 (en) Cytotoxic peptides and antibody drug conjugates thereof
NZ602734A (en) Therapeutic dll4 binding proteins
WO2012178022A3 (en) Therapeutic applications targeting sarm1
EA200971077A1 (ru) Гетероциклические модуляторы киназы
WO2014031487A8 (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same
AR102595A1 (es) Anticuerpos anti-ang2 y métodos de utilización
PH12013500410B1 (en) Vegf-binding molecules
WO2017151971A3 (en) METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
MX2015005122A (es) Conjugados de farmaco-proteina novedosos.
TR201909747T4 (tr) Aktarım.

Legal Events

Date Code Title Description
FG Grant or registration